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Background: Twenty-five patients with Niemann Pick disease type C (age range: 7 months to 44 years) were
enrolled in an Italian independent multicenter trial and treated with miglustat for periods from 48 to 96 months.
Methods: Based on the age at onset of neurological manifestations patients’ phenotypes were classified as: adult
(n = 6), juvenile (n = 9), late infantile (n = 6), early infantile (n = 2). Two patients had an exclusively visceral
phenotype. We clinically evaluated patients’ neurological involvement, giving a score of severity ranging from 0 (best)
to 3 (worst) for gait abnormalities, dystonia, dysmetria, dysarthria, and developmental delay/cognitive impairment,
and from 0 to 4 for dysphagia. We calculated a mean composite severity score transforming the original scores
proportionally to range from 0 to 1 to summarize the clinical picture of patients and monitor their clinical course.
Results: We compared the results after 24 months of treatment in 23 patients showing neurological manifestations.
Stabilization or improvement of all parameters was observed in the majority of patients. With the exception of
developmental delay/cognitive impairment, these results persisted after 48–96 months in 41 – 55% of the patients
(dystonia: 55%, dysarthria: 50%, gait abnormalities: 43%, dysmetria: 41%, respectively). After 24 months of therapy
the majority of the evaluable patients (n = 20), demonstrated a stabilization or improvement in the ability to
swallow four substances of different consistency (water: 65%, purée: 58%, little pasta: 60%, biscuit: 55%). These
results persisted after 48–96 months in 40-50% of patients, with the exception of water swallowing. Stabilization or
improvement of the composite severity score was detected in the majority (57%) of 7 patients who were treated
early (within 3.5 years from onset) and rarely in patients who received treatment later.
Conclusions: The results of this study suggest that miglustat treatment can improve or stabilize neurological
manifestations, at least for a period of time; the severity of clinical conditions at the beginning of treatment can
influence the rate of disease progression. This conclusion applies particularly to patients with juvenile or adult
onset of the disease.
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Niemann-Pick disease type C (NPC) is a lysosomal lipid-
storage disorder, with an autosomal recessive mode of
inheritance, characterized by defective intracellular lipid
trafficking, and secondary accumulation of free choles-
terol, sphingosine and glycosphingolipids in the lysosome-
late endosome compartment of different tissues and
organs. The brain is particularly affected by this patho-
logical accumulation.
NPC is estimated to affect 1 in 150,000 live births and
can be genetically caused by mutations in either the NPC1
gene (more than 95% of all NPC cases) or the NPC2 gene
(the remaining 5%).
NPC is clinically characterized by a wide spectrum of
visceral and neurological signs and symptoms, with vari-
able age of onset [1]. Classically, NPC disease has been
classified in many phenotypes based on the patient’s age
of onset, independently from whether the first signs were
visceral or neurological [1]. More recently, categorization
of patients has been based on the age at onset of the first
neurological sign [2].
Neurological findings in NPC include vertical and hori-
zontal supranuclear gaze palsy, ataxia, dysarthria, dyspha-
gia, dystonia, seizures, progressive dementia, psychiatric
syndromes and gelastic cataplexy. These manifestations
have a continuous, unbroken progression, consistently
more rapid in patients diagnosed in early childhood, com-
pared with those with later onset [3]. Visceral symptoms
include hepatosplenomegaly and pulmonary infiltrates.
No treatment was available for NPC patients until 2004,
when miglustat (NB-DNJ, Zavesca®, Actelion Pharmaceu-
ticals, Ltd) was proposed for the treatment of the disease
[4]. Miglustat is a small iminosugar molecule able to cross
the blood–brain barrier and to reversibly inhibit glucosyl-
ceramide synthase, which is the first enzyme in glyco-
sphingolipid synthesis.
The efficacy of miglustat on progression of neuro-
logical manifestations has been studied in NPC patients
enrolled in international clinical trials and observa-
tional studies. Data from one-year treatment of juvenile
and adult NPC patients enrolled in an international
standard randomized controlled trial [5] suggested that
miglustat improves or stabilizes several neurological
manifestations.
Data from long-term treatment of ten affected children
enrolled in a parallel, uncontrolled study [6] and from pa-
tients participant to further studies [7-13] confirmed the
previous results and extended them to pediatric patients,
also suggesting that the magnitude of the effect was
greater in juvenile and adult subjects [14].
Miglustat has been approved by the European Agency
of Medicines in 2009 for the treatment of neurological
manifestations in NPC patients. Nonetheless experience
is still limited and long-term efficacy is unknown.We report the results of an independent multicenter
clinical trial of miglustat treatment in Italian patients,
carried out from 2007 to 2009, before the drug was ap-
proved in Europe, and from long-term follow-up, lasting
up to 48–96 months.
Methods
Patients
Twenty-five NPC patients were enrolled at 11 Italian
clinical centers. Enrolled patients were diagnosed on the
basis of biochemical tests (filipin staining and LDL-
cholesterol esterification) and/or molecular analysis of
NPC1 or NPC2 genes.
Patients were classified in four clinical forms based on
the age at onset of the first neurological symptoms and
signs [2]: Early Infantile (EI): ≤ 2 years of age; Late Infantile
(LI) : > 2 and ≤5 years of age); Juvenile (J): > 5 and ≤16 years
of age; Adult (A): >16 years of age.
The disease phenotype of two patients was exclusively
visceral (V) as they did not show any neurological mani-
festation at start of treatment. One of them was diagnosed
at 0.6 years of age for a prolonged cholestatic jaundice and
hepatosplenomegaly (V14); the other one was the youn-
ger brother (V23) of a patient already showing the LI
form and was diagnosed at 1.3 years, due to the pres-
ence of splenomegaly.
One patient (J15) (who was the sister of a juvenile pa-
tient) was treated very early, at the first appearance of
neurological manifestations, consisting of minimal slurred
speech. Her phenotype was classified as a J form.
Table 1 summarizes patients’ cohort characteristics. We
enrolled familial cases in 4 groups of siblings (J15 and J16;
LI08 and V23; A02 and A19; J06, J12 and J13). Additional
file 1 summarizes individual patients’ phenotype, duration
of miglustat treatment and follow-up, and latency between
onset of neurological manifestations and start of treat-
ment. Some patients have been reported in the literature
in the meantime (J15, J16, SI22, LI09 in Fecarotta et al.
[15]; LI08, V14, V23, in Di Rocco et al. [9]; LI 21, J11,
LI05, J07, J12, J13 and A01 in Ginocchio et al. [13]).
Study design
Enrolled patients represented all known NPC Italian
patients in the years 2007–2009. A subset of 11 patients
was already on miglustat treatment at enrollment (the
drug was paid from the National Health service as an
off-label prescription). As a consequence, this study was
partly conceived as a single arm, open label, clinical trial
and partly as an observational study, to evaluate the effi-
cacy of miglustat therapy in NPC patients. A long-term
follow-up, up to 48–96 months of treatment was estab-
lished in enrolled patients.
The study was carried out in accordance with criteria
and procedures outlined in the declaration of Helsinki
Table 1 Patients’ demographic, molecular and clinical features
Early-infantile
phenotype
Late-infantile
phenotype
Juvenile
phenotype
Adult
phenotype
Visceral
phenotype
All
patients
Number of patients 2 6 9 6 2 25
Gender
male 2 1 3 2 1 9
female 0 5 6 4 1 16
Number of Adult patients (Age >16 years at
start of treatment)
0 1 2 6 0 9
Number of Pediatric patients (Age ≤ 16 years
at start of treatment)
2 5 7 0 2 16
Age at diagnosis (years)
Mean (SD) 1.63 (1.37) 6.69 (4.22) 11.38 (2.55) 28.42 (8.55) 0.94 (0.51) 12.73 (10.69)
Range 0.66 - 2.60 0.25 - 10.6 7.70 - 16.00 18.00 - 43.83 0.58 - 1.30 0.25 - 43.83
Age at enrollment (years)
Mean (SD) 3.0 (0.06) 10 (4.18) 16 (3.12) 32 (8.89) 2.0 (0.53) 16 (11.72)
Range 2.66 - 2.75 3.10 - 15.66 10.3 - 19.60 18.83 - 43.83 2.33 - 1.58 1.58 - 43.83
Age at start of treatment (years)
Mean (SD) 1.83 (1.3) 9.53 (4.45) 15.31 (3.5) 31.93 (8.95) 1.09 (0.72) 15.69 (11.59)
Range 0.91 - 2.75 3.0 - 16.7 9.41 - 19.60 19.00 - 43.83 0.58 -1.60 0.58 - 43.83
Time between onset of first neurological
manifestation and start of treatment
(LAG) (years)
Mean (SD) 0.71 (0.66) 6.22 (4.23) 6.24 (4.26) 8.74 (3.84) 0 5.97 (4.49)
Range 0.66 - 0.75 1.00 - 12.70 0.41 - 11.83 3.00 - 13.80 0 (0–13.80)
Number of patients on miglustat treatment
at enrollment
1 2 5 2 1 11
Duration of previous miglustat treatment
at enrollment (months)
Mean (SD) 11.0 (14.85) 4.0 (7.27) 11.0 (13.0) 9.0 (12.60) 11.0 (15.56) 9.0 (11.13)
Range 0 - 21 0 - 18.0 0 - 31.0 0 - 23.0 0 - 22.0 6.0 - 31.0
Duration of miglustat treatment (months)
Mean (SD) 72.0 (33.94) 67.0 (12.5) 76.0 (16.7) 68.0 (22.34) 72.0 (16.97) 71.0 (22.11)
Range 48.0 - 96.0 48.0 - 84.0 54.0 - 96.0 48.0 - 96.0 60.0 - 84.0 48.0 - 96.0
Molecular analysis
NPC1 gene mutations (n. of patients) 1 6 9 5 2 23
NPC2 gene mutations (n. of patients) 1 0 0 1 0 2
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guidelines. Local Ethics Committee approval and written
informed consent from all patients or their legal repre-
sentatives were obtained before enrollment.
The study was supported by the Italian Medicines
Agency (Agenzia Italiana del Farmaco, AIFA, Rome,
trial number FARM59T23W; EUDRACT number 2006-
005842-35) and the trial started in 2007, before miglu-
stat was commercially approved for the treatment of
neurological manifestations in NPC disease.Treatment regimen
Patients over 16 years of age received orally 200 mg t.i.d.
of miglustat (NB-DNJ, Zavesca®, Actelion Pharmaceuti-
cals, Ltd), if tolerated, with dosage reduction in the case
of drug-related adverse events, while younger patients
received the drug with dosage adjusted to body surface
area, corresponding to a range of 220–300 mg/m2/day
(total daily dose between 100 and 600 mg/day). One
pediatric patient (LI17) who had already started treatment
before enrollment in the study, (age at start of treatment
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patients (600 mg/day), as administered before enrollment.
Three patients over 16 years (LI25, J13 and J20) who did
not tolerate the regimen for adults of 600 mg/day, re-
ceived a reduced dosage, between 300 and 500 mg/day
corresponding to a dosage per surface area similar to
that of pediatric patients.
Methods
Primary endpoints were chosen to clinically evaluate the
efficacy of miglustat on neurological signs and symp-
toms and were defined as stabilization or improvement
of neurological involvement including swallowing ab-
normalities. Safety was monitored by registration of ad-
verse events and changes in physical or biochemical
parameters. The evaluated parameters were gait abnor-
malities, dysmetria, dystonia, dysarthria, developmental
delay/cognitive impairment and dysphagia. The outcome
was established comparing the assessment at baseline with
the last available evaluation in each patient.
In 14 patients who had not been treated with miglustat
at the enrollment, the baseline was defined as the neuro-
logical assessment at the start of treatment and data were
prospectively collected; in 11 patients who were already
on treatment at the enrollment in the trial, the baseline
data were retrospectively retrieved.
Rating scale of neurological parameters
Each parameter was evaluated on a 4- or 5-point scale
and the overall severity of the neurological status, including
dysphagia, was summarized using a mean composite sever-
ity score (MCSS). The original scoring was then modified
by assigning a score from 0 (best) to 1 (worst), to give
equal weight to each parameter (Additional file 2).
Gait abnormalities, dysmetria, dystonia, dysarthria and
developmental delay/cognitive impairment were assessed
by the same neurologist at each participating center,
assigning a 4-points score.
Additionally, developmental delay/cognitive impairment
was also assessed in selected patients using formal psycho-
metric tests as Griffith’s mental developmental scale and
Wechsler-Bellevue scale (WPPSI, WISC-R, WAIS-R). Ra-
ven’s Progressive Matrices Test was used in a single pa-
tient (J11) with severe dysarhtria to measure non-verbal
reasoning. Psychometric tests were chosen according to
patient’s age and clinical conditions. In each patient the
same test was administered by the same specialist, if
appropriate for age and clinical conditions, to compare
subsequent assessments.
When psychometric evaluations were available, pa-
tients were categorized according to the classification of
the American Association of Mental Retardation, the
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5) (Additional file 2).Dysphagia was clinically assessed, assigning a score
to patient’s ability of swallowing four substances of dif-
ferent consistencies (water, purée, little pasta and bis-
cuit), according to a 5-point score, in agreement with
methods used in previous international clinical trials
[5]. Dysphagia was also assessed using videofluoro-
scopic swallowing study (VFSS) in 4 pediatric patients,
to provide additional information on patterns of im-
pairment of the swallowing mechanism and to detect
aspiration [15].
Data analysis
The two patients with the visceral phenotype were eval-
uated separately from the other 23 neurologically symp-
tomatic patients.
Absolute values and changes from baseline in individ-
ual scores were analyzed using descriptive statistics.
For gait abnormalities, dysmetria, dystonia and dys-
arthria, we did not evaluate any change from baseline
for those patients who had the most severe score at
baseline (completely invalidating the specific function)
and who did not show any improvement following
miglustat treatment. Neither gait abnormalities nor
dysarthria were evaluated in a patient (EI22) younger
than 12 months at baseline because physiologically un-
able to walk and speak.
For developmental delay/cognitive impairment, when
finer psychometric evaluations were available, two pa-
tients (LI09 and LI17) within the severe/invalidating cat-
egory were judged evaluable for changes from baseline,
even if they remained in the same most severe category
after treatment, because improvement, stabilization or
deterioration were actually based on the two subcat-
egories of severe and profound intellectual disability,
respectively. Similarly, patients within the first category
for developmental delay/cognitive status (absence of
cognitive/psychomotor impairment) were defined as
stable, improved or deteriorated based on the two sub-
categories of absent and borderline intellectual disabil-
ity, respectively.
A mean composite severity score (MCSS) was also
calculated, including all parameters, as the mean of the
individual modified scores in each patient, at baseline
and at each follow-up visit. In patient EI22 the MCSS
was calculated at baseline assigning the modified score
to dystonia, dysmetria, developmental delay/cognitive
impairment and dysphagia and the mean of modified
scores was calculated on the 4 evaluated parameters,
while all the subsequent evaluations were performed on
all six parameters.
Considering that the most severe swallowing difficul-
ties had been detected for liquids in all patients, we
scored the dysphagia parameter in the MCSS referring
to the swallowing of water.
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Severity scores: distribution at baseline and change after
treatment
Severity score for each parameter was assessed at baseline
in 23 patients with neurological manifestations. Severity
score distribution showed that clinical conditions of pa-
tients at baseline were largely heterogeneous (Additional
file 3 A).
We studied the effects of miglustat, assessing the
change of severity for each parameter. Results were sum-
marized as the proportion of patients showing improve-
ment (I), stabilization (S) or deterioration (D) for each
parameter from baseline to the last available evaluation,
as previously defined.
Among evaluable patients, most of them showed im-
provement or stabilization of the severity score after
24 months of treatment for gait abnormalities (I = 7%; S =
79%), dystonia (I = 10%; S = 70%), dysmetria (I = 11%; S =
50%), dysarthria (I = 13%; S = 56%), developmental delay/
cognitive impairment (I = 10.5%; S = 58%) and dysphagia
(water dysphagia: I = 20%; S = 45%). With the exception of
developmental delay/cognitive impairment, these results
persisted in 41 – 55% of the patients (in 55% for dys-
tonia, 50% for dysarthria, 43% for gait abnormalities and
41% for dysmetria) after 48–96 months of treatment
(Additional file 3 B).
While stabilization was more prevalent, improvement
of some neurological parameters was seen in few patients.
We did not consider as improved one patient (EI22) that
was not evaluated at baseline for gait abnormalities and
dysarthria (as he was younger than 12 months) and that
acquired ambulation and speech during the miglustat
treatment. In this patient, who showed the severe p.E20X
homozygous mutation in the NPC2 gene and had a severe
neurological involvement at baseline, psychometric tests
surprisingly evidenced a sustained improvement, with
progress in reaching psychomotor milestones. While a
progressive decline over time was expected, according to
the natural history of the disease, the Developmental Quo-
tient as assessed by Griffith's mental developmental scale
changed from 45 (chronological age, CA = 11 months) to
63 after 24 months of therapy, (CA = 38 months) and the
Intelligence Quotient as assessed by WPSSI was 61 after
36 months of treatment (CA = 4 years). However, deterior-
ation of the mental status was observed in the long-term
follow-up and IQ was measured as 52 after 48 months (at
CA = 5 years).
Among enrolled patients, three had a severe dysphagia
at enrollment and food and drug were administered using
a percutaneous enterogastrostomy (PEG) (Additional
file 3 C). Using qualitative tests for the clinical assess-
ment of swallowing in 20 evaluable patients, we showed
improvement or stabilization of ability to swallow 4 dif-
ferent substances in most of patients (water: I + S = 65%,purée: I + S = 58%, little pasta: I + S = 60%, biscuit: I + S =
55%) after 24 months of therapy; these results persisted in
40 – 50 % of patients after 48–96 months, with the excep-
tion of water swallowing (Additional file 3D).
We observed a late severe worsening of dysphagia, re-
quiring the application of a PEG, in a single late-treated
patient (A02), after years of stabilization during miglu-
stat treatment.
Video-fluoroscopic swallowing study, additionally used
in 4 children treated with miglustat for 3 years or more,
showed a clear-cut improvement in 3 patients with ab-
normalities at baseline. The patient (J15) who had not
shown any swallowing abnormality at baseline remained
stable [15] after 84 months of treatment.
Clinical course evaluated by the mean composite severity
score (MCSS)
We calculated a MCSS in every patient at each visit
during the long-term follow-up to summarize the course
and evolution of neurological manifestations. Patients were
stratified based on three parameters: phenotypic form, la-
tency between neurological onset and start of treatment
(LAG) and severity of clinical conditions at treatment base-
line, to evaluate which parameters could affect the re-
sponse to treatment.
Long-term stabilization or improvement of the MCSS
was shown in some patients with adult (1/6) and juvenile
(3/9) phenotypes (Figure 1). The two patients with vis-
ceral phenotypes (V14 and V23) who were treated with
the aim to prevent the onset of neurological manifesta-
tions, did not show any neurological symptom and sign
after 60 and 84 months of treatment, respectively (data
not shown) [9].
Patients with early onset of the disease showed neither
long-term stabilization nor improvement, even if they
responded well to treatment in the first 24 months
(Figure 1).
Improvement or stabilization of the MCSS were no-
ticed in the majority (5/9; 56%) of patients who received
an early treatment (less than 3.5 years from the onset),
but just in a single patient (A10) who received a late
treatment (1/16; 6.25%) (Figure 2).
The severity of clinical conditions at start of treatment
was related to the progression rate. All patients with the
most severe neurological involvement (MCSS > 0.5) did
not show any improvement, while patients who were
treated even with very mild neurological involvement
were stable after 7 years of treatment. Progression of the
disease was variable in patients with low and intermedi-
ate MCSS (Figure 3).
We particularly analyzed the juvenile phenotype group,
which was the most numerous one, and noted that, even
among patients with a similar severity score at baseline
(between 0.1 and 0.50), those who received an early
Figure 1 Evolution over time of the mean composite severity score (MCSS) of neurologically symptomatic patients during miglustat
treatment. Patients with a) adult (n = 6), b) juvenile (n = 10), c) late infantile (n = 5) and d) early infantile (n = 2) phenotypes.
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showed a better response than those who were treated
later (Additional file 4).
Comparison of miglustat efficacy in siblings
We analyzed two couples of siblings who presented a
discrepancy in the LAG category and in the severity of
conditions at baseline. In the first pair (J15 and J16),
one patient started the treatment immediately at the on-
set of very mild neurological signs and symptoms; she
remained stable and did not develop further neuro-
logical manifestations to the end of follow-up. At her
same age, her older sister, despite miglustat treatment
for 5 years, showed a serious neurological involvement,
with a MCSS of 0.56 (Additional file 5 A). Similarly, in
the other pair of sibs (LI08 and V23), the latter, who re-
ceived the diagnosis before the onset of neurological
symptoms, based on his sister’s infantile phenotype and
the presence of isolated splenomegaly, started the treat-
ment at 19 months of life and did not show any neuro-
logical involvement until the end of the trial [9]. The
older sister (LI08) started the treatment with a LAG of5.25 years and her clinical conditions progressively
worsened (Additional file 5 B).
We studied another couple of sibs who were in the same
LAG category > 7 years (A02 and A19). Both patients
showed a similar progression of the disease, even though
one of them had a milder phenotype at the start of treat-
ment (Additional file 5 C).
Finally, two (J12 and J13) of three sisters were both
treated early (within 3.5 years from onset), and showed a
similar stabilization of their conditions. Differently, the
third sibling (J06) who started treatment with a longer la-
tency (LAG> 7 years) showed a slow progression of the
disease (Additional file 5 D).
Safety evaluation
During the treatment, the following adverse events were
detected in different patients: epistaxis and thrombo-
cytopenia, insomnia, leukopenia, behavioral problems,
extrapyramidal symptoms, tremors, hypertransaminase-
mia, weight loss, diarrhea.
Weight loss and diarrhea were the most common ad-
verse events during miglustat treatment.
Figure 2 Evolution over time of the mean composite severity score (MCSS) during miglustat treatment in different groups of patients,
classified for the latency between the onset of neurological manifestations and start of therapy (LAG). Patients with a) LAG ≤ 3.5 years
(n = 7); b) LAG between >3.5 and ≤ 7 years (n = 7); c) LAG > 7 years (n = 9).
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old girl affected by epilepsy, who was hospitalized for
uncontrolled seizures. Appropriate anticonvulsant therapy
was prescribed. The patient was discharged after the
control of seizures was reached. According to the investi-
gator, this event was related to the disease and not to the
study treatment.
None of the reported adverse events was life threatening.Discussion
We describe an Italian cohort of 25 NPC patients who
were treated with miglustat for 4–8 years.
We collected clinical data for the first 24 months of
therapy, partly prospectively in patients enrolled in an
independent clinical trial and partly retrospectively in
patients already on miglustat treatment; a prospective
observational study was continued up to 24–72 months
Figure 3 Evolution over time of the mean composite severity score (MCSS) during miglustat treatment in different groups of
neurologically symptomatic patients, classified for the MCSS at baseline. Patients with a) MCSS ≤ 0.1 (n = 2), b) patients with MCSS
between > 0.1 and ≤ 0.3 (n = 3), c) patients with MCSS > 0.3 and ≤ 0.5 (n = 7) and d) patients with MCSS > 0.5 (n = 11).
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with the first sponsored clinical trials for the commercial
approval of miglustat [5,6].
Features of patients’ series
We report data from 11 patients with neurological mani-
festations younger than 16 years of age at start of miglu-
stat therapy, who were treated for 48–96 months. To
our knowledge such a long term follow-up has not been
previously reported in a large pediatric case series.
The clinical experience of long-term miglustat treat-
ment in children before 16 years of age is still limited in
previous studies [7-13] since some of these described sin-
gle cases or small series of children with heterogeneous
conditions, treated for variable periods [7,9,11,13].
Large cohorts of NPC children were previously re-
ported [6,8,10,12], but the follow-up was shorter than
36 months, except in three patients from the series re-
ported by Pineda [8] and in one patient reported by
Hèron [10].
Two patients had only visceral signs and started treat-
ment before miglustat had been approved only for the
treatment of neurological manifestations.Set up of a severity scoring scale
In NPC disease there are no biochemical markers, used
to evaluate the efficacy of treatment, that clearly corre-
lates with the severity of clinical manifestations. We set
up a clinical scoring scale for a series of neurological pa-
rameters such as gait abnormalities, dysmetria, dystonia,
dysarthria developmental delay/cognitive impairment and
dysphagia. This severity score system was designed before
the publication of various studies using the NPC disability
score or its modification [16]. Our original score is slightly
different, but actually equivalent to the NPC disability
score, since it evaluated similar neurological areas and
allowed the assessment of disease evolution over time.Evolution of neurological manifestations in the case series
The 23 neurologically symptomatic patients showed an
extreme heterogeneity in terms of clinical conditions at
start of treatment, even in the same phenotypic subgroup.
After miglustat treatment, in the short-term follow-up
(24 months) we detected the stabilization or improvement
of all parameters in the majority of patients (Additional
file 3). After such a short-term observation, these results
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erature [5,6,8].
At the end of the long-term follow-up (48–96 months
after start of treatment), improvement or stabilization
was still present in approximately half of patients, with
the exception of developmental delay/cognitive impair-
ment (Additional file 3). The results were striking en-
couraging for dysphagia, as previously reported [15].
The improvement or stabilization of swallowing ability
for a long time might represent a major clinical benefit
for NPC patients, in terms of immediate impact on the
quality of life and decreased risk of aspiration, with a
consequent longer survival [17].
Parameters affecting the response to miglustat treatment
In addition to the evaluation of each parameter in the
overall population of neurologically symptomatic patients,
we tried to examine the evolution of the CNS involve-
ment in each patient, that is more relevant to understand
the efficacy of miglustat treatment. Similarly to previously
reported studies, we calculated a MCSS, equivalent to the
NPC composite disability score [16], to summarize the
clinical evolution of each patient during treatment.
Given the wide variability of the clinical course in the
patients’ population, our study was aimed at under-
standing which parameters could affect the response to
treatment. We stratified the patients’ population based
on clinical phenotype, MCSS at baseline and latency be-
tween onset of neurological manifestations and start of
treatment (LAG).
Consistently with previously reported data [14], pa-
tients with late-onset phenotypes, such as Juvenile or
Adult ones, showed better responses to treatment than
patients with an early onset phenotype, who worsened in
the long-term follow-up, even when they had shown im-
provement or stabilization of neurological manifestations
in the first 24 months of therapy. This initial improvement
or stabilization was associated with a shorter interval be-
tween the onset of symptoms and the start of treatment in
three patients (LI21, EI24, EI22), who already presented
obvious neurological manifestations, as discussed later.
As expected, patients who showed less severe symp-
toms when they started miglustat treatment responded
better than patients who already showed more severe
clinical conditions. Moreover, the patients treated earlier
(within 3.5 years from the onset) had better response to
treatment than those who had longer time intervals be-
tween the onset of neurological manifestations and the
start of treatment. This was particularly evident by ana-
lyzing a larger phenotype subgroup, as that of juvenile
patients (Additional file 4), also including pairs of sibs.
The disease progression was stopped for more than 7 years
in one of two sibs (J15), who was treated at the first ap-
pearance of minimally slurred speech.Even among five juvenile patients who had similar
conditions at start of treatment, with a MCSS between
0.1 and 0.5, two early treated sisters improved (J12, J13),
while three patients treated later (J16, J06, J04) (includ-
ing the third sister of two early treated sibs), showed
progressive deterioration.
These data suggested that, even with comparable clin-
ical conditions at the start of treatment, the latency be-
tween the onset of symptoms and the beginning of the
treatment was the most important parameter to prevent
a rapid deterioration and lead to a longer stabilization of
neurological manifestations.
Treatment of asymptomatic patients
At the moment, there is still an open question on the de-
cision of starting treatment with miglustat in neurologic-
ally symptom-free patients and if it may delay the onset
and progression of neurological manifestations. When we
enrolled in our trial two NPC patients showing visceral
phenotype or sibs without neurological manifestations,
miglustat had not been approved for NPC treatment,
and neither clinical indication nor efficacy on visceral
symptoms were known.
In our case series miglustat treatment was started in
a child showing isolated splenomegaly, treated even be-
fore the onset of any neurological manifestation (V23) [9]
because he was the brother of a symptomatic child.
Current recommendations on miglustat treatment state
that a confirmed NPC diagnosis should not be taken as
the only indication for immediate miglustat therapy, since
neurological, psychiatric and/or cognitive manifestations
can take a long time to appear [18]. However, it is difficult
to decide which is the appropriate time to start treating a
still symptom-free sib of an already symptomatic patient.
Even considering an intrafamilial phenotypic variability,
the absence of neurological manifestations in V23 at
6.5 years of age, suggested the efficacy of miglustat to pre-
vent neurological manifestations for a long time in neuro-
logically asymptomatic patients. Therefore, we think that
the treatment of sibs should be considered on a case-by-
case basis, taking into account parents’ expectations and
pressures to start miglustat treatment as soon as possible.
A still open issue remains the treatment of infants
presenting with isolated visceral manifestations without
a family history, as our case V14. The aim of miglustat
treatment in these patients should be the prevention of
the onset of neurological symptoms and signs, but we
think that monitoring the response to treatment is cur-
rently impossible in absence of a good biomarker correl-
ating with neurological involvement.
Efficacy of treatment in the NPC2 subset of patients
Until now information is scarce on the efficacy of miglu-
stat treatment in patients with proven NPC2 mutations,
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single experiences or anecdotal reports [10].
We treated from 11 months of age a 9-year-old child
(EI22) with a homozygous nonsense mutation (p.E20X)
of the NPC2 gene, after a short latency of 5 months
from the onset of first neurological signs. After miglustat
treatment he showed a progressive improvement of the
developmental/intelligence quotient, which persisted after
36 months of treatment. Then, his neurological status pro-
gressively deteriorated in the long-run, but improvement
of swallowing ability was sustained over time. The im-
provement of dysphagia was associated to improvement of
growth parameters [15] (and perhaps to a longer sur-
vival, compared to his older affected brother, who died
at 10 months of age).
The observed evolution in this patient is quite differ-
ent from the natural history in infantile patients with the
p.E20X mutation of NPC2 gene, who usually show a ser-
ious, precocious and rapidly progressive neurological in-
volvement [19,20]. Whether early initiation of treatment
in this patient influenced the clinical course has to be
confirmed by further cases.
We also treated an adult patient (A03), showing the
c.26 T > C (p.L9P) homozygose mutation of the NPC2
gene. Patients with missense mutations of the NPC2 gene
showed variable phenotypes, including juvenile and adult
onset forms [19,20]. Miglustat treatment was started very
late, after a latency of more than 10 years from the neuro-
logical onset. The clinical course was characterized by a
progressive neurological deterioration, similarly to adult
patients with mutations in NPC1, who were treated late.
Our data in patients with mutations in NPC2, although
limited to single cases, suggested that the outcome of pa-
tients with NPC2 gene mutations could not differ from
that of the NPC1 group. Similarly to them the response to
miglustat therapy could be affected by the same parame-
ters, such as phenotype, severity of conditions at start of
therapy and latency between the onset of neurological
manifestations and the start of treatment.
Limitations and biases
We are aware of limitations and biases of the present
study, due to its design and to the clinical heterogeneity
of patients.
First, this study was partly interventional, and partly
observational, as some patients had already started treat-
ment with the investigated medicinal product at the mo-
ment of the official enrollment in the trial.
Enrolled patients were heterogeneous, both genetic-
ally (23 patients had mutations of NPC1 and 2 pa-
tient had mutations of NPC2), and phenotypically (we
included patients with variable age of presentation).
Age range was also wide and patients included in the
same phenotypic category had heterogeneous clinicalconditions at enrollment, from pre-symptomatic to very
severe conditions.
Our study also lacked a control group and the evolu-
tion of severity scores before treatment was unknown.
Conclusions
Our data suggested that an early diagnosis and treatment
were important to benefit from miglustat therapy, particu-
larly in juvenile and adult onset disease. Consistently with
the ability of miglustat to cross the blood–brain-barrier, our
data supported the published evidence that the substrate
reduction has some efficacy in modifying the natural course
of neurological manifestations in NPC disease [5-15].
Finally, considering that natural history of NPC disease
is characterized by a linear progression of neurological
symptoms [3,21], our results indicated that later onset
phenotypes, milder neurological manifestations and earl-
ier start of miglustat treatment were associated with
stabilization or even improvement of clinical conditions,
at least for some time.
Additional files
Additional file 1: Patients’ phenotype and genotype, duration of
miglustat treatment and follow-up, latency between onset of
neurological manifestations and start of treatment.
Additional file 2: Severity rating scale of neurological
manifestations and dysphagia.
Additional file 3: Distribution of severity score of five neurological
parameters at baseline and after 24 and 48–96 months of
treatment. A: The severity score distribution for gait abnormalities,
dystonia, dysmetria, dysarthria and developmental delay/cognitive
impairment showed heterogeneous clinical conditions in enrolled
patients at baseline B: Modification of severity score of five neurological
parameters, compared to baseline, after 24 and 48–96 months of
treatment. After 24 months of treatment most patients showed
improvement or stabilization of the severity score for gait abnormalities,
dystonia, dysmetria, dysarthria and developmental delay/cognitive
impairment. C: Distribution of severity score for swallowing of four different
substances at baseline and after 24 and 48–96 months of treatment. The
severity score distribution for swallowing ability showed heterogeneous
clinical conditions in enrolled patients at baseline. D: Modification of
severity score for swallowing of four different substances, compared to
baseline, after 24 and 48–96 months of treatment. After 24 months of
treatment most patients showed improvement or stabilization of the ability
to swallow four substances with different consistencies. Abbreviations: I =
improvement; S = stabilization; D = deterioration.
Additional file 4: Evolution over time of the mean composite
severity score (MCSS) during miglustat treatment in juvenile
patients, based on the latency between the onset of neurological
manifestations and start of therapy (LAG). Patients with a) LAG ≤
3.5 years (n = 3); b) LAG >3.5 years (n = 6).
Additional file 5: Evolution over time of the mean composite severity
scores (MCSS) in groups of siblings. In sections a) and b) siblings were
treated with different latency between the onset of neurological
manifestations and start of therapy (LAG); in section c) siblings were both
treated with LAG > 7 years. In section d) both patients J12 and J13 were
treated early (LAG < 3,5 years), while patient J06 had a longer latency.
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